Network meta-analysis of 31 RCTs (4,092 adults with non-CF bronchiectasis): vs placebo, macrolides (RR 0.44) and DPP-1 inhibitors (RR 0.73) reduced exacerbation rates (moderate certainty); only DPP-1 inhibitors clearly reduced severe exacerbations (RR 0.70).
Meta-analysisn = 4,092
Yamamoto et al. Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis